AI
| Followers | 839 |
| Posts | 120588 |
| Boards Moderated | 13 |
| Alias Born | 09/05/2002 |
Tuesday, June 28, 2011 3:45:54 PM
Roche reports detailed Lucentis/DME data from US phase-3 studies:
http://finance.yahoo.com/news/Two-Pivotal-Phase-III-bw-202584487.html?x=0&.v=1
Curiously for two identical studies, RIDE showed a dose response, but RISE did not:
The top-line data from these studies were reported in Mar 2011 (#msg-60818771, #msg-61386067). FDA approval of Lucentis in DME should be a shoo-in; ever since Lucentis first showed efficacy in AMD many years ago, there has been little doubt that it would work in DME also. Lucentis is already approved for DME in the EU based on trials conducted by NVS (#msg-58523789).
http://finance.yahoo.com/news/Two-Pivotal-Phase-III-bw-202584487.html?x=0&.v=1
Curiously for two identical studies, RIDE showed a dose response, but RISE did not:
The top-line data from these studies were reported in Mar 2011 (#msg-60818771, #msg-61386067). FDA approval of Lucentis in DME should be a shoo-in; ever since Lucentis first showed efficacy in AMD many years ago, there has been little doubt that it would work in DME also. Lucentis is already approved for DME in the EU based on trials conducted by NVS (#msg-58523789).
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
